Search form
Search
About us
Oxurion at a glance
Our milestones
Our mission
Our team
Partnerships
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
Science team
Investors
Shareholder Information
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
Archived Events
News & Events
Latest news
Media contact
Contact
Menu
About us
Oxurion at a glance
Our milestones
Our mission
Our team
Partnerships
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
Science team
Investors
Shareholder Information
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
Archived Events
News & Events
Latest news
Media contact
Contact
Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye
THR-149 - Further readings
Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model
Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy.
Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs
Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Inhibitory effect of a novel bradykinin B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice.
Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats.
Plasma kallikrein and diabetic macular edema.
Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients.
Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
The kallikrein-kinin system in diabetic retinopathy. Prog. Drug Res. 69, 111-143.